User:MdWikiBot/Semaglutide
Clinical data | |
---|---|
Trade names | Ozempic, Rybelsus, Wegovy, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618008 |
Pregnancy category |
|
Routes of administration | Subcutaneous, by mouth[2] |
Drug class | GLP-1 agonist[2] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 89% |
Metabolism | Proteolysis |
Elimination half-life | 1 week |
Duration of action | 63.6 h |
Excretion | Urine and faeces |
Chemical and physical data | |
Formula | C187H291N45O59 |
Molar mass | 4,113.64 g·mol−1 |
3D model (JSmol) | |
| |
|
Semaglutide, sold under the brand names Ozempic among others, is a medication used to treat type 2 diabetes and obesity.[2] It is less preferred to metformin, though they may be used together.[2][3] It improves blood sugar control, decreases the risk of heart disease, and decreases the risk of kidney problems.[2] It is used by mouth or by injection under the skin.[2]
Common side effects including nausea, vomiting, diarrhea, abdominal pain, and constipation.[2] Serious side effects may include diabetic ketoacidosis, low blood sugar, and pancreatitis.[3] There are concerns that use during pregnancy may harm the baby and use when breastfeeding is not recommended.[2] It works like human glucagon-like peptide-1 (GLP-1) and increases insulin release, decreases glucagon release, and slows stomach emptying.[3]
Semaglutide was approved for medical use in the United States in 2017.[2] It was developed by Novo Nordisk.[2] It was the first GLP-1 that can be taken by mouth.[4] In the United Kingdom 2 mg for injection costs the NHS about £73 as of 2020.[3] This amount in the United States costs about 850 USD as of 2021.[5]
References
change- ↑ "Semaglutide Use During Pregnancy". Drugs.com. Archived from the original on 17 April 2021. Retrieved 16 April 2021.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 "Semaglutide Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 16 January 2021. Retrieved 2 April 2021.
- ↑ 3.0 3.1 3.2 3.3 3.4 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 738. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link) - ↑ "FDA approves first oral GLP-1 treatment for type 2 diabetes" (Press release). FDA. 20 September 2019. Archived from the original on 23 September 2019. Retrieved 20 September 2019.
- ↑ "Ozempic Prices, Coupons & Savings Tips". GoodRx. Archived from the original on 5 September 2021. Retrieved 16 April 2021.